FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3031645457> ?p ?o ?g. }

• W3031645457 endingPage "1038" @default.
• W3031645457 startingPage "1029" @default.
• W3031645457 abstract "Effects of resveratrol on metabolic health have been studied in several short-term human clinical trials, with conflicting results. Next to dose, the duration of the clinical trials may explain the lack of effect in some studies, but long-term studies are still limited.The objective of this study was to investigate the effects of 6-mo resveratrol supplementation on metabolic health outcome parameters.Forty-one overweight men and women (BMI: 27-35 kg/m2; aged 40-70 y) completed the study. In this parallel-group, double-blind clinical trial, participants were randomized to receive either 150 mg/d of resveratrol (n = 20) or placebo (n = 21) for 6 mo. The primary outcome of the study was insulin sensitivity, using the Matsuda index. Secondary outcome measures were intrahepatic lipid (IHL) content, body composition, resting energy metabolism, blood pressure, plasma markers, physical performance, quality of life, and quality of sleep. Postintervention differences between the resveratrol and placebo arms were evaluated by ANCOVA adjusting for corresponding preintervention variables.Preintervention, no differences were observed between the 2 treatment arms. Insulin sensitivity was not affected after 6 mo of resveratrol treatment (adjusted mean Matsuda index: 5.18 ± 0.35 in the resveratrol arm compared with 5.50 ± 0.34 in the placebo arm), although there was a significant difference in postintervention glycated hemoglobin (HbA1c) between the arms (P = 0.007). The adjusted means showed that postintervention HbA1c was lower on resveratrol (35.8 ± 0.43 mmol/mol) compared with placebo (37.6 ± 0.44 mmol/mol). No postintervention differences were found in IHL, body composition, blood pressure, energy metabolism, physical performance, or quality of life and sleep between treatment arms.After 6 mo of resveratrol supplementation, insulin sensitivity was unaffected in the resveratrol arm compared with the placebo arm. Nonetheless, HbA1c was lower in overweight men and women in the resveratrol arm. This trial was registered at Clinicaltrials.gov as NCT02565979." @default.
• W3031645457 created "2020-06-05" @default.
• W3031645457 creator A5012395602 @default.
• W3031645457 creator A5022874682 @default.
• W3031645457 creator A5025735308 @default.
• W3031645457 creator A5041552031 @default.
• W3031645457 creator A5049850291 @default.
• W3031645457 creator A5053939956 @default.
• W3031645457 creator A5070391533 @default.
• W3031645457 creator A5087038295 @default.
• W3031645457 date "2020-06-03" @default.
• W3031645457 modified "2023-10-18" @default.
• W3031645457 title "No effect of resveratrol supplementation after 6 months on insulin sensitivity in overweight adults: a randomized trial" @default.
• W3031645457 cites W1573282459 @default.
• W3031645457 cites W1826835110 @default.
• W3031645457 cites W1971966796 @default.
• W3031645457 cites W1984225039 @default.
• W3031645457 cites W1987616871 @default.
• W3031645457 cites W1997952678 @default.
• W3031645457 cites W1999999378 @default.
• W3031645457 cites W2003504981 @default.
• W3031645457 cites W2023324581 @default.
• W3031645457 cites W2024872626 @default.
• W3031645457 cites W2032004838 @default.
• W3031645457 cites W2032034048 @default.
• W3031645457 cites W2038317187 @default.
• W3031645457 cites W2041811148 @default.
• W3031645457 cites W2071062711 @default.
• W3031645457 cites W2071551339 @default.
• W3031645457 cites W2073487625 @default.
• W3031645457 cites W2074601722 @default.
• W3031645457 cites W2075638146 @default.
• W3031645457 cites W2084534703 @default.
• W3031645457 cites W2088381487 @default.
• W3031645457 cites W2094139493 @default.
• W3031645457 cites W2097146819 @default.
• W3031645457 cites W2097285161 @default.
• W3031645457 cites W2117499294 @default.
• W3031645457 cites W2120007830 @default.
• W3031645457 cites W2130955150 @default.
• W3031645457 cites W2133795831 @default.
• W3031645457 cites W2144600435 @default.
• W3031645457 cites W2144770293 @default.
• W3031645457 cites W2151487996 @default.
• W3031645457 cites W2154031058 @default.
• W3031645457 cites W2159212679 @default.
• W3031645457 cites W2160005693 @default.
• W3031645457 cites W2160427616 @default.
• W3031645457 cites W2165712074 @default.
• W3031645457 cites W2165722123 @default.
• W3031645457 cites W2170869159 @default.
• W3031645457 cites W2269780386 @default.
• W3031645457 cites W2401973189 @default.
• W3031645457 cites W2528106147 @default.
• W3031645457 cites W2590432212 @default.
• W3031645457 cites W2605543159 @default.
• W3031645457 cites W2612116387 @default.
• W3031645457 cites W2767935537 @default.
• W3031645457 cites W2781647169 @default.
• W3031645457 cites W2791089458 @default.
• W3031645457 cites W2801147755 @default.
• W3031645457 cites W2791777222 @default.
• W3031645457 doi "https://doi.org/10.1093/ajcn/nqaa125" @default.
• W3031645457 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7528554" @default.
• W3031645457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32492138" @default.
• W3031645457 hasPublicationYear "2020" @default.
• W3031645457 type Work @default.
• W3031645457 sameAs 3031645457 @default.
• W3031645457 citedByCount "37" @default.
• W3031645457 countsByYear W30316454572020 @default.
• W3031645457 countsByYear W30316454572021 @default.
• W3031645457 countsByYear W30316454572022 @default.
• W3031645457 countsByYear W30316454572023 @default.
• W3031645457 crossrefType "journal-article" @default.
• W3031645457 hasAuthorship W3031645457A5012395602 @default.
• W3031645457 hasAuthorship W3031645457A5022874682 @default.
• W3031645457 hasAuthorship W3031645457A5025735308 @default.
• W3031645457 hasAuthorship W3031645457A5041552031 @default.
• W3031645457 hasAuthorship W3031645457A5049850291 @default.
• W3031645457 hasAuthorship W3031645457A5053939956 @default.
• W3031645457 hasAuthorship W3031645457A5070391533 @default.
• W3031645457 hasAuthorship W3031645457A5087038295 @default.
• W3031645457 hasBestOaLocation W30316454571 @default.
• W3031645457 hasConcept C126322002 @default.
• W3031645457 hasConcept C134018914 @default.
• W3031645457 hasConcept C142724271 @default.
• W3031645457 hasConcept C168563851 @default.
• W3031645457 hasConcept C204787440 @default.
• W3031645457 hasConcept C27081682 @default.
• W3031645457 hasConcept C2776816829 @default.
• W3031645457 hasConcept C2777180221 @default.
• W3031645457 hasConcept C2777538456 @default.
• W3031645457 hasConcept C2780221984 @default.
• W3031645457 hasConcept C2780586474 @default.
• W3031645457 hasConcept C535046627 @default.
• W3031645457 hasConcept C555293320 @default.
• W3031645457 hasConcept C71924100 @default.
• W3031645457 hasConcept C98274493 @default.

• next